Deals channel feed – Endpoints News

Deals channel feed

GSK bags Tesaro for $5B as it leaps back into commercial oncology and beefs up cancer drug pipeline

7 years ago

Giant Roche wades into the preclinical NLRP3 pool, bagging Jecure for their anti-inflammatory team at Genentech

7 years ago

Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains

7 years ago

Immunotherapy developer Enlivex uses Bioblast shell to reverse merge its way onto Nasdaq

7 years ago

Tesaro stock soars on another report the PARP player is exploring a sale

7 years ago

Introducing SVB Leerink: SVB bags Leerink Partners for $280M as a major player spreads its wings during a life sciences boom

7 years ago

With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan

7 years ago

Are more immuno-oncology buyouts on the menu at Eli Lilly’s executive suite?

7 years ago

From zero to hero: Endocyte’s little deal a year ago spurred a comeback capped by $2.1B Novartis buyout

7 years ago

Seeking cash to fund PhIII for once-failed drug, Adynxx rides Alliqua's shell to Nasdaq

7 years ago

Blackstone bags Clarus, staking out a growing PhIII niche for itself in a rapidly changing biopharma industry

7 years ago

Roche scoops up a Treg player for the I/O team, plucking 1 drug and spinning off a 2nd into a new biotech

7 years ago

Alexion gambles on an early-stage drug for rare diseases, bagging Apple Tree-backed Syntimmune in $1.2B buyout

7 years ago

Allergan chief snaps up a rival biotech for $195M in cash, plus. Deal beefs up the aesthetics pipeline

7 years ago

Supernus bags early-stage CNS drug for $15M upfront in renewed epilepsy R&D efforts

7 years ago

Takeda starts to assemble a list of products it plans to auction off after Shire buyout — report

7 years ago

Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal

7 years ago

Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger

7 years ago

Traditionalists at Takeda spark a family feud with CEO Christophe Weber over his $62B Shire takeover deal

7 years ago

Novo Nordisk buys university spinout Ziylo — adding a potential remedy for hypoglycemia to its diabetes pipeline

7 years ago

Astellas grabs a biotech toddler in $109M buyout deal for a glaucoma gene therapy program

7 years ago

Once a multibillion dollar company, OvaScience ends a pennystock vehicle for Millendo's reverse merger

7 years ago

With high expectations on Provenge, Dendreon is 'sold' (again) in $832M deal

7 years ago

Game change: Pfizer doubles down on its late-stage pipeline as CEO Read disavows a long reliance on M&A deals

7 years ago

First page Previous page 108 109 110111112 113 114 Next page Last page